Program
Bupivacaine
Also written as “HTX-011”, “SKY0402” and “Bupivacaine HCl”.
Its studies are mostly in Pain, Postoperative · Pain · Hernia, Inguinal · Bunion · Hemorrhoids, led by 10 companies.
Drug pageBupivacaine: every studyMany companies study it; this page follows only the 56 they lead. All 1,200 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pacira BioSciencesits history only | 230 open or running | phase 4since Oct 24, 2011 | Jun 11, 2007 | none ahead |
| Heron Therapeuticsits history only | 171 open or running | phase 4since Oct 10, 2018 | Jun 9, 2015 | none ahead |
| Innocollits history only | 60 open or running | phase 3since Aug 12, 2015 | Oct 18, 2010 | none ahead |
| Bausch Health Companiesits history only | 20 open or running | phase 3since Oct 9, 2015 | Mar 30, 2010 | none ahead |
| Cristália Produtos Químicos Farmacêuticos Ltda.its history only | 20 open or running | phase 3since Feb 23, 2011 | Feb 23, 2011 | none ahead |
| Jiangsu HengRui Medicine | 22 open or running | phase 4since Mar 13, 2024 | Mar 13, 2024 | Nov 2026phase 2 · NCT06529432 |
| Ascension Healthits history only | 10 open or running | phase 3since Nov 20, 2019 | Nov 20, 2019 | none ahead |
| Liquidia Technologiesits history only | 10 open or running | phase 1since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| Rebel Medicineits history only | 11 open or running | phase 2since Apr 28, 2026 | Apr 28, 2026 | none ahead |
| Tian Medicalits history only | 10 open or running | phase 4since Oct 16, 2012 | Oct 16, 2012 | none ahead |
Also a collaborator on its studies: Pfizer, Premier Research Group and Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2024First study: phase 4 study in Local Analgesia Via InfiltrationFirst studyNCT06344091 · 232 planned · China
- Jul 26, 2024Phase 2 study in Local Analgesia Via Nerve BlockNCT06529432 · 96 planned · China
- Sep 28, 2026Primary completion moved from 2026-09-28 to 2027-05Date moved laterphase 4 · +8 months · NCT06344091
Ahead
- Nov 2026Primary completion: phase 2 study in Local Analgesia Via Nerve BlockNCT06529432
- May 2027Primary completion: phase 4 study in Local Analgesia Via InfiltrationNCT06344091
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06529432Local Analgesia Via Nerve Block · China | 2 | Recruiting | Nov 2026 | 96 |
| NCT06344091Local Analgesia Via Infiltration · China | 4 | Recruiting | May 2027 | 232 |
How it is read
Names in the registry
- “HTX-011”, 20 entries
- “SKY0402”, 12 entries
- “Bupivacaine HCl”, 7 entries
- “Bupivacaine”, 5 entries
- “Bupivacaine Liposome Injection”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 27 studies
- Pain, 5 studies
- Hernia, Inguinal, 4 studies
- Bunion, 3 studies
- Hemorrhoids, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.